Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
The purpose of this study is to assess the efficacy and safety of everolimus 10mg daily in patients with advanced gastric carcinoma (inoperable, recurrent or metastatic gastric cancer) whose cancer has progressed despite prior treatment.
Advanced Gastric Cancer
DRUG: Everolimus
To Assess disease control rate (DCR) as defined CR + PR + SD assessed by RECIST criteria, 18 months
Objective response rate (ORR) assessed by RECIST criteria, 18 months|To assess progression free survival (PFS) and overall survival (OS), 18 months|To describe the safety profile (incidence and severity of adverse events, serious adverse events) assessed by NCI CTCAE version 3.0, 18 months
The purpose of this study is to assess the efficacy and safety of everolimus 10mg daily in patients with advanced gastric carcinoma (inoperable, recurrent or metastatic gastric cancer) whose cancer has progressed despite prior treatment.